Ananda Scientific Inc., a clinical-stage drug development company, and Benta SAS have signed a Memorandum of Understanding (MOU) which expresses the parties’ intent to explore a potential collaboration focused on accelerating the development and future availability of a new treatment for Post-Traumatic Stress Disorder (PTSD) in Europe and the Middle East/North Africa (MENA) region.

PTSD affects millions of people worldwide, yet there has been no new approved drug for PTSD in over two decades — underscoring a critical unmet medical need.

As part of its clinical development pipeline, Ananda Scientific is currently advancing Nantheia, an investigational drug product being evaluated in clinical trials for the treatment of PTSD. Under the terms of the MOU, Ananda Scientific will continue to lead all aspects of clinical development, while Benta will focus on leveraging Benta’s manufacturing expertise and infrastructure to support potential future product development, scale-up, and regional distribution across Europe and the MENA region.

“This MOU represents an important step in our mission to deliver innovative therapies for neuropsychiatric disorders where patients have limited treatment options,” said Sohail Zaidi, CEO of Ananda Scientific Inc. “There is an urgent and growing global need for new therapies for PTSD. With our Nantheia clinical development program, we are advancing a promising candidate through rigorous clinical evaluation, and potential collaborations such as this can help ensure readiness for future manufacturing and distribution.”

“At Benta, we are committed to supporting the advancement of transformative therapeutics that can have a real impact on patients’ lives,” said Bernard Tannoury, President of Benta SAS (France). “We are pleased to explore opportunities to contribute our manufacturing capabilities and technical expertise to support Ananda Scientific’s efforts in bringing innovative PTSD treatments to patients in Europe and the MENA region.”

This MOU underscores both companies’ shared interest in advancing mental health care through scientific innovation and high-quality pharmaceutical development aimed at improving outcomes for patients affected by PTSD.